СПИСОК ЛИТЕРАТУРЫ

  1. Araujo F.G., Shepard R.M., Remington J.S. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur. J. Clin. Microbiol. Infect. Dis., 1991, 10: 519-524.
  2. Leport C., Vilde J.L., Katlama C., et al. Failure of spiramycin to prevent neurotoxoplasmosis in immunosuppressed patients. JAMA, 1986, 255: 2290.
  3. Decazes J.M., Doco-Lecompte T., Modai J. Echec de fortes doses de roxithromycine dans le traitement de la toxoplasmose cerebrale des patients atteints de SIDA. In: Reunion Interdisciplinaire de Chimiotherapie Antiinfectieuse. Paris, 1988: abstr. 202/C12.
  4. Leport C., Fernandez-Martin J., Morlat P., et al. Combination of pyrimethamine-clarithromycin for acute therapy of toxoplasmic encephalitis. A pilot study in 13 AIDS patients. In: The 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990: abstr. 1158.
  5. Young L.S. Macrolides as antimycobacterial agents. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 121-129.
  6. Havlir D.V., Dube M.P., Sattler F.R., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N. Engl. J. Med., 1996, 335: 392-398.
  7. Chang H.R., Pechere J.C. Macrolides in toxoplasmosis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 131-140.
  8. Ji B., Jamet P., Perani E.G., et al. Powerful bactericidal activity of clarithromycin and minocycline against Mycobacterium leprae in the treatment of lepromatous leprosy. J. Infect. Dis., 1993, 168: 188-190.
  9. Young L.S. Atypical mycobacteria. In: Textbook of AIDS Medicine. Broder S., Merigan T.C., Bolognesi D. (Eds.). Baltimore, 1993: 283-294.
  10. Gorzynski E.A., Gutman S.I., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob. Agents Chemother., 1989, 33: 591-592.
  11. Luna-Herrera J., Reddy V.M., Gangadharam P.R.J. Synergistic effect of clarithromycin and isoniazid and rifampin against tubercle bacilli. In: The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, 1994: abstr. E134.
  12. Massarotti E.M., Luger S.W., Rahn D.W., et al. Treatment of Lyme disease. Am. J. Med., 1992. 92: 396-403.
  13. Strle F., Ruzic E., Cimperman J. Erythema migrans comparison of treatment with azithromycin, doxycycline and phenoximethylpenicillin. J. Antimicrob. Chemother., 1992, 30: 543-550.
  14. Freeman E. Periodontal disease. Part III. Chemotherapeutics. Can. Fam. Physician, 1988, 34: 1395-1397.
  15. Mills W.H., Thompson G.W., Beagrie G.S. Clinical evaluation of spiramycin and erythromycin in control of periodontal disease. J. Clin. Periodontol., 1979, 6: 308-316.
  16. Chin Quee T., AI-Joburi W., Lautar-Lemay C., et al. Comparison of spiramycin and tetracycline used adjunctively in the treatment of advanced chronic periodontitis. J. Antimicrob. Chemother., 1988, 22 (suppl. B): 171-177.
  17. Desnica B., Burek V., Makek N. Azithromycin/ranitidine combined treatment of H.pylori in patients with duodenal ulcer and chronic gastritis - a pilot study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.22.
  18. Lamouliatte H., Courrier A., Mion F., et al. Roxithromycin 300 mg b.i.d. in association with amoxycillin and lansoprazole on eradication of Helicobacter pylori: results of an open, non-comparative, multicentre study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Roxithromycin Posters: 22.
  19. Saikku P., Leinonen M., Mattila K., et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet ii, 1988: 983-985.
  20. Saikku P. Chlamydia pneumoniae and cardiovascular disease. Clin. Microbiol. Infect., 1996, 1 (suppl. 1): S19-22.
  21. Gupta S., Leatham E.W., Carrington D., et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation, 1997, 96; 404-407.
  22. Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link? Lancet, 1997, 350: 430-436.
  23. Gupta S., Leatham E.W., Carrington D., et al. The effect of azithromycin in post myocardial infarction patients with elevated Chlamydia pneumoniae antibody titres. J. Am. Coll. Cardiol., 1997, 29 (suppl. A): 209A.
  24. Gurfinkel E., Bozovich G., Daroca A., et al. Randomised trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet, 1997, 350: 404-407.
  25. Kraft M., Cassell G.H., Aerni M., et al. Mycoplasma pneumoniae as a cofactor in the pathogenesis of chronic asthma. In: European Respiratory Society. Annual Congress. Berlin, 1997; abstr. P0292.
  26. Blasi F., Cosentini R., Fagetti L., et al. Chlamydia pneumoniae and sarcoidosis. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P2097.
  27. Frangova-Youroukova V., Ivanov S., Popov G. Chlamydia pneumoniae and respiratory tract diseases in Bulgaria. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P2096.
  28. Herbaut A.G., Dachy A., Thys J.P. Chemoprophylaxis for bacterial meningitis, Acta Clin. Belg., 1986, 41: 402-410.
  29. Prevention of Recurrent Attacks of Rheumatic Fever. Recommendation of AHA Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council of Cardiovascular Disease in the Young. Circulation, 1988, 78: 1082.
  30. Dajani A.S., Taubert K.A., Wilson W., et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Clin. Cardiol., 1997, 277: 1794-1801.
  31. Van Scoy R.E., Wilkowske C.J. Prophylactic use of antimicrobial agents in adult patients. Mayo Clin. Proc., 1992, 76: 288-292.
  32. Anderson S.L., Berman J., Kuschner R. Prophylaxis of Plasmodium falciparum malaria azithromycin administered to volunteers. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 8.15.
  33. . Linares J., Garau J., Dominiquez C., et al. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community acquired pneumococcal disease. Antimicrob. Agents Chemother., 1983, 23: 545-547.
  34. Acar J.F., Buu-Hoi A.Y. Resistance patterns of important gram-positive pathogens. J. Antimicrob. Chemother., 1988, 21 (suppl. C): 41-47.
  35. Maruyama S., Yoshioka H., Fujita K., et al. Sensitivity of group A streptococci to antibiotics. Am. J. Dis. Child., 1979, 133: 1143-1145.
  36. Stratchounsky L., Krechikova 0., Bolmstrom A., et al. Susceptibility patterns of clinical strains of Streptococcus pyogenes in Russia. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. C-71.
  37. Leclerq R., Courvalin P. Intrinsic and unusual resistance to macrolides, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother., 1991, 35: 1273-1276.
  38. Garrod L.P., Lambert H.P., O'Grady F. Antibiotic and Chemotherapy. 5th ed. Edinburgh, 1981: 183.
  39. Mapple P.A.C., Hamilton-Miller J.M.T. Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet, 1989, 1: 537-539.
  40. Vanhoff R., Gordts B., Dierickx R., et al. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni. Antimicrob. Agents Chemother., 1980, 18: 118-121.
  41. Brittain D.C. Erythromycin. Med. Clin. North. Am., 1987, 71: 1147.
  42. Sabath L.D., Gerstein D.A., Loder P.B., et al. Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. Lab. Clin. Med., 1968, 72: 916-923.
  43. Jao R.L., Finland M. Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro. Am. J. Med. Sci., 1967, 253: 639-650.
  44. Niitu Y., Hasegawa S., Kubota H. In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae. Antimicrob. Agents Chemother., 1974, 5: 513-519.
  45. Washington J.A., Wilson W.R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (I). Mayo Clin. Proc., 1985, 60: 189-203.
  46. Giving erythromycin by mouth. Drug Therap. Bull., 1995, 33: 77-79.
  47. Antibacterial Products and Markets. Scrip Reports. 1997: 59-72.
  48. Janicki R.S., Garnham J.C., Worlaud M.C., et al. Comparison of erythromycin ethylsuccinate, stearate and estolat treatments of group A streptococcai infections of the upper respiratory tract. Clin. Pediatr., 1975, 14: 1098-1107.
  49. Ginsburgh C.M., McCracken J.G.U., Crow S.D., et al. Erythromycin therapy for group A streptococcal pharyngytis: results of comparative study of the estolate and ethylsuccinate formulations. Am. J. Dis. Child., 1984, 138; 536-539.
  50. Страчунский Л.С. Оптимизация антибактериальной терапии новорожденных детей. Автореф. докт. дисс. - М., 1993.
  51. Butler D., Kuhn R.J., Chandler M.H.H. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet., 1994, 26: 374-395.
  52. Bryskier A., Butzler J.P. Macrolides. In: Antibiotic and chemotherapy: anti-infective agents and their use in therapy. O'Grady E., Lambert H.P., Finch R.G., Greenwood D. (Eds.). Churcill Livingstone. New York, etc., 1997: 377-393.
  53. Howard J.E., Nelson J.D., Clahsen J., et al. Otitis media of infancy and early childhood. Am. J. Dis. Child., 1976, 130: 965-970.
  54. Washington J.A. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (II). Mayo Clin. Proc., 1985, 60: 271-278.
  55. Disse В., Gundert-Remy U., Weber E., et al. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int. J. Clin. Pharmacol. Ther. Toxicol., 1986, 24: 460-464.
  56. Ellsworth A.J., Christensen D.B., Voipone-McMahon M.T. Prospective comparison of patient tolerance to enteric-coated vs. nonenteric-coated erythromycin. J. Fam. Pract., 1990, 31: 265-270.
  57. Tolman K.G., Sannella J.J., Freston J.W. Chemical structure of erythromycin and hepatotoxicity. Ann. Int. Med., 1974, 81: 58-60.
  58. Pessayre D., Larrey D., Funck-Brentano C., et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J. Antimicrob. Chemother., 1985, 16 (suppl. A): 181-194.
  59. Ball A.P. Therapeutic considerations for the management of respiratory tract infection: the role of new macrolides and fluoroquinolones. Infec. Med., 1991, 8 (suppl. A): 7-17.
  60. Reese R.E., Betts R.F. Antibiotic use. In: A Practical Approach to Infectious Diseases. Reese R.E., Betts R.F. (Eds.). 3rd ed. Boston etc., 1991: 821-1007.
  61. Schonenberger R.A., Haefel W.E., Weiss P., et al. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). Br. Med. J., 1990, 300: 1375-1376.
  62. Farrar H.C., Walsh-Sukys M.C., Kyllonen К., et al. Cardiac toxicity associated with inytravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr. Infect. Dis. J., 1993, 12: 688-691.
  63. Haefeli W.E., Schoenenberger R.A., Weiss P., et al. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med., 1992, 18: 469-473.
  64. Zhang Z.Q., Antzelevitch С. Erythromycin produces prominent action potential prolongation and early after depolarization-induced triggered activity in M but not epicardial and endocardial regions of the canine ventricle. Circulation, 1993, 88 (suppl. С): 1753.
  65. Haydon R.C., Thaelin J.W., Davis W.E. Erythromycin ototoxicity: Analysis and conclusions based on 22 case reports. Otolaryngol. Head Neck Surg., 1984, 92: 678-684.
  66. Swanson D.J., Sung R.J., Fine M.J., et al. Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am. J. Med., 1992, 92: 61-68.
  67. Disney F.A., Downton M.I., Higgins J.E., et al. Comparison of once-daily cefadroxil and four-times-daily erythromycin in Group A streptococcal pharyngitis. Adv. Ther., 1990, 7: 312-326.
  68. Milatovic D. Evaluation of cefadroxil, penicillin and erythromycin in the treatment of streptococcal tonsillopharyngitis. Pediatr. Infect. Dis., 1991, 10: 61-63.
  69. Lisby-Sutch S., Nemec-Dwyer M., Deeter R.G., et al. Therapy of otitis media. Clin, Pharm., 1990, 9: 15-34.
  70. Kirby B.D., Snyder K.M., Myer R.D., et al. Legionnairs' disease: Report of sixty-five noaocomially acquired cases and review of the literature. Medicine, 1980, 59: 188-205.
  71. Muder R.F., Yu V.L., Zuravleff M.S. Pneumonia due to the Pittsburgh pneumonia agent: New clinical perspective with a review of the literature. Medicine, 1983, 62: 120-128.
  72. Dournon E., Mayaud С., Wolff M., et al. Comparison of the activity of three antibiotic regimens in severe Legionnairs' disease. J. Antimicrob, Chemother., 1990, 26 (suppl. В): 129-139.
  73. Sprauer M.A., Cochi S.L., Zell E.R., et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J. Dis. Child., 1992, 146: 177-181.
  74. Atmar R.L., Greenberg S.В. Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Semin. Resp. Infect., 1989, 4: 19-31.
  75. Grayston J.I. Chlamydia pneumoniae strain TWAR pneumonia. Ann. Rev. Med., 1992, 43: 317-323.
  76. Schlick W. The problems of treating atypical pneumonia. J. Antimicrob. Chemother., 1993, 31 (suppl. С): 111-120.
  77. Waites К.В., Sims P.J., Crouse D.T., et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. Pediatr. Infect. Dis. J., 1994, 13: 287-293.
  78. Eady E.A., Holland К.Т., Cunliff W.L. The use of antibiotics in acne therapy: oral or topical administration? J. Antimicrob, Chemother., 1982, 10: 89-115.
  79. Goldstein E.J.C. Bite wounds and infection. Clin. Infect. Dis., 1992, 14: 633-640.
  80. Anders B.J., Lauer B.A., Paisley J.W., et al. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet, 1982, 1: 131-132.
  81. Berger T.G. Dermatologic care in the AIDS patient. In The Medical Management of AIDS. Sande M.A., Volberding P.A. (Eds.). Philadelphia, 1992: 151.
  82. Clarke J.S., Condon R.E., Fenton L.J., et al. Preoperative oral antibiotics reduce septic complications of colon operations; Results of prospective randomized, double-blind clinical study. Ann. Surg., 1977, 186: 251-259.
  83. Handbook of Antimicrobial Therapy. The Medical Letter on Drug and Therapeutics. New Rochelle, NY: Medical Letter, 1992.
  84. Spector S.L., Katz F.H., Farr R.S. Troieandomycin; effectiveness in steroid-dependent asthma and bronchitis. J. Allergy Clin. Immunol, 1974, 6: 367-379.
  85. Paulsen 0. Roxithromycin - a macrolide with improved pharmacokinetic properties. Drugs Today, 1991, 27: 193-222.
  86. Kohno S., Hara K., Matsumoto F. A review of Japanese studies of roxithromycin. Pharmacokinetics, microbiology and clinical studies, particularly in the treatment of respiratory infection. Drug Invest., 1993, 5: 93-97.
  87. Rolston K.V., Ho D.V., LeBlanc B. Comparative in vitro activity of the new erythromycin derivative dirithromycin against Grampositive bacteria isolated from cancer patients. Eur. J. Clin. Microbiol, 1990, 9: 30-33.
  88. Tejada M., Malizia T., Marchetti F., et al. In vitro synergic interaction of roxithromycin with proton pump inhibitors and bismuth subcitrate against Helicobacter pylori. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Roxithromycin Posters: 14.
  89. Perez-Trallero E., Alcorta M., Montes M., et al. Comparative activity of macrolides against H.pylori. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. E62.
  90. Samra Z., Rosenberg S., Kaufman L. Antibiotic susceptibility of Ureaplasma urealyticum. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 146.
  91. Samra Z., Rosenberg S., Luzon A. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.04.
  92. Bryskier A., Bretz A.G., Peter 0. Lyme disease - in vitro activity of the combination of roxithromycin and minocycline against the three subspecies of B.burgdorferi, In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 1.07.
  93. Rastogi N., Seng Gon K., Bryskier A. Activity of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin and clofazimine against the Mycobacterium avium complex. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: absrt. 299.
  94. Romand S., Derouin F. Synergism of roxithromycin and pyrimethamin or sulfadiazine against Toxoplasma gondii. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 334-340.
  95. Young R.A., Gonzalez J.P., Sorkin E.M. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs, 1989,37: 8-41.
  96. Rolin 0., Bouanchaud D.H. Comparison of in vitro post-antibiotic effect induced by 14-membered-ring macrolides (erythromycin and roxithromycin) and 16-membered-ring macrolides ( josamycin and spiramycin) in Staphylococcus aureus. Pathol. Biol., 1989, 37: 375-377.
  97. Moneib N.A., Shibl A.M., El-Said M.A., et al. Macrolides induced suppression of virulence factors produced by Staphylocoocus aureus. J. Chemother., 1993, 5: 289-292.
  98. Konno S., Asano K., Kurokawa M., et al. Antiasthmatic activity of a macrolide antibiotic: analysis of possible mechanisms in vitro and in vivo. Int. Arch. Allergy Appl. Immunol., 1994, 105: 308-316.
  99. Wongtim S., Charoenlap P., Limthongkul S., et al. Effect of roxithromycin on bronchial hyperresponsiveness in patients with cough variant asthma. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3028.
  100. Koyama M., Tateno M., Shirotsuka M., et al. Absorbtion, metabolism and excretion of RU 28965 in humans. Chemotherapy, 1988, 36 (suppl. 4): 164-183.
  101. Saito A., Kato Y., Odagaki E., et al. Pharmacokinetics and clinical results of RU 28965. Chemotherapy, 1988, 36 (suppl. 4): 216-223.
  102. Shiba K., Saito A., Shimada J., et al. Basic and clinical studies on RU 28965. Chemotherapy, 1988, 36 (suppl. 4): 292.
  103. Begue P., Kafetzis D.A., Albin H., et al. Pharmacokinetics of roxithromycin in paediatrics. J. Antimicrob. Chemother., 1987, 20 (suppl. B): 101-106.
  104. Masaki M., Inoue Y., Mashimoto H., et al. Laboratory and clinical studies on RU 28965. Chemotherapy, 1988, 36 (suppl. 4): 421-437.
  105. Hoffler D., Koeppe P., Sorgel F., et al. The parmacokinetics of roxithromycin in dialysis patient. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: abstr. 260.
  106. Babany G., Roulot D., Chretien P., et al. Pharmacokinetics of single and repeated oral doses of roxithromycin in patients with cirrhosis. In: The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 222.
  107. Wehrmann T., Rudolph U., Lembcke B., et al. Roxithromycin and erythromycin exert different effects on postprandial antroduodenal motor function and gastrointestinal symptoms in healthy subjects. Eur. J. Gastroenterol. Hepatol., 1993, 5: 829-834.
  108. Esteban A., Molina M.J., Soto C. Acute cholestatic hepatitis due to roxithromycin. Rev. Clin. Esp., 1993, 192: 352-353.
  109. Pedersen F.M., Bathum L., Fenger C. Acute hepatitis and roxithromycin. Lancet, 1993, 341: 251-252.
  110. Pecquet S., Chachaty E., Tancrede C., et al. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob. Agents Chemother., 1991, 35: 548-552.
  111. Niki Y., Soejima R. Roxithromycin does not affect electrocardiograms of healthy volunteers in the case of concomitant use with terfenadine. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.34.
  112. Nilsen 0. Roxithromycin does not change terfenadine pharmacokinetics or electrocardiology. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.33.
  113. Kees F., Ittner K.P., Mair G., et al. Kinetic synergism: omeprazole and roxithromycin. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 4222.
  114. Pechere J.-C. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn. Microbiol. Infect. Dis., 1992, 15 (suppl. 4): 111S-117S.
  115. Lorenz J. Multicenter study on the efficacy and tolerance of roxithromycin in the treatment of respiratory tract Infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 413-417.
  116. Saldarriaga A. Roxithromycin, 150 mg bid, for treatment of sinusitis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 435-438.
  117. DeCampora E., Camaioni A., Leonardi M. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn. Microbiol. Infect. Dis., 1992, 15 (suppl. 4): 119S-122S.
  118. Cooper B.C., Mullins P.R., Jones M.R., et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae. A meta-analysis of 12 clinical studies. Drug Invest., 1994, 7: 299-314.
  119. Portier H. Overview of the efficacy and safety of roxithromycin versus control antibiotics in the treatment of infections in adults. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 403-408.
  120. Bisetti A., Grassi L., Fiorucci F., et al. Open randomized comparison of activity and tolerance of roxithromycin vs clarithromycin in the treatment of lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 271.
  121. Stamboulian D., Perianu M. The efficacy of roxithromycin (300 mg once daily or 150 mg BID) in the treatment of "atypical" pneumonia in an international multicentre study. In: The 17th International Congress of Chemotherapy. Berlin, 1991.
  122. Antela A., Guerrero A., Escudero R., et al. Efficacy and safety of roxithromycin as empiric therapy for lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 278.
  123. Agache P., Amblard P., Moulin G., et al. Roxithromycin in skin and soft tissue infections. J. Antimicrob. Chemother., 1987, 20 (suppl. B): 153-156.
  124. Nohara N., Akagi M., Kanzaki H. Comparative double blind test of roxithromycin and josamycin on purulent diseases. Chemotherapy Tokyo, 1989, 37: 1518-1519.
  125. Bernard P., Plantin P., Roger H., et al. Roxithromycin versus penicillin in he treatment of erysipelas in adults: a comparative study. Br. J. Dermatol., 1992, 127: 155-159.
  126. Choroszy-Krol I., Ruczkowska J. Roxithromycin (Rulid) in the treatment of chlamidial urethritis in men. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.25.
  127. Negostani N., d’Antuono A. Efficacy of roxithromycin vs minocycline in the treatment of non gonococcal urethritis: clinical and microbiological aspects. In: The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 252.
  128. Narimatsu A., Ito T., Ono M., et al. Chlamidial infections in the fields of ginecology and obstetrics. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: abstr. 283.
  129. Rosales M., Dominguez V., Bonacho I. Roxithromycin versus doxycycline in the treatment of cervicitis due to Chlamidia trachomatis in asymptomatic women. Rev. Clin. Esp., 1993, 192: 253-255.
  130. Bircher A.J., Gelzer D., Rufli T. Roxithromycin in the treatment of non-gonococcal urethritis. A double blind comparison of two treatment regimens. In: The 16th Congress of Chemotherapy. Jerusalem, 1989: abstr. 226.
  131. Hansen K., Hovmark A., Lebech A.-M., et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venerol., 1992, 72: 297-300.
  132. Gasser R., Wendelin I., Reisinger E., et al. Combined therapy with roxithromycin and co-trimoxazole in Lyme disease. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 508-515.
  133. Uip D.E., Lima A.L.M., Amato V.S., et al. The use of roxithromycin in the diarrhea caused by Cryptosporidium spp. associated to AIDS. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 7.27.
  134. Okamoto S., Haruma K., Kawaguchi H., et al. Study on eradication of Helicobacter pylori by the combination use of roxithromycin, bismuth subnitrate, and omeprazole. In: The 18th International Congress of Chemotherapy. Stockholm, 1993: 282.
  135. Burette A., Glupczynski Y., Deprez C., et al. Lansoprazole plus roxithromycin and metronidazole for eradication of Helicobacter pylori: results of pilot study. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 520-523.
  136. Damann H.-G., Walter T.A. Roxithromycin, metronidazole and roxatidine acetate triple therapy and H.pylori eradication rates. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.24.
  137. Durant J., Hazime F., Bernard E., et al. An open randomized study of roxithromycin efficacy and tolerance in the primary prevention of pneumocystosis and cerebral toxoplasmosis in 52 HIV-patients. In: The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, 1991: abstr. 1216.
  138. Rahn R., Linde H.J., Riffel C., et al. Macrolides in prophylaxis for endocarditis. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 516-519.
  139. Kern W.V., Hay B., Kern P., et al. Efficacy of roxithromycin to prevent viridans streptococcal bacteriemia following cytotoxic chemotherapy. A randomized trial in patients with acute leukemia and bone marrow transplant patients receiving ofloxacin prophilaxis. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 314.
  140. Bazet M.C., Blanc F., Chumdermpadetsuk S., et al, Roxithromycin in the treatment of paediatric infections. Br. J. Clin. Pract., 1988, 42 (suppl. 55): 117-118.
  141. Casellas J.M., Rodriguez H.A., Fernandez-Macloughlin G.J., et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br. J. Clin. Pract., 1988, 42 (suppl. 55): 113-114.
  142. Stamboulian D., Fernandez-Macloughlin G.J., Lanoel J.L., et al, Clinical evaluation of roxithromycin in 101 children. Br. J. Clin. Pract., 1988, 42 (suppl. 55): 115-116.
  143. Salvarezza C., Villar E., Ballario M. Estudio comparativo de la eficacia y tolerancia clinica de roxitromicina vs. amoxicillina en neumopatia extrahospitalarias en pediatria. Prensa Med. Argent., 1989, 76: 127-130.
  144. Guggenbichler J.P. First results of a new formulation of roxithromycin: a randomized controlled study in lower respiratory tract infections in infants and children. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.24.
  145. Laurencena E., Forti M.J. Roxithromycin in the treatment of acute otitis media in children. Prensa Med. Argent., 1992, 79: 577-579.
  146. Haentjes M., Levy J., De Boeck M., et al. Early treatment with roxithromycin of campylobacter associated enteritis in children. In: The 16th Congress of Chemotherapy. Jerusalem, 1989.
  147. Hardy D.J., Swanson R.N., Rode R.A., et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother., 1990, 34: 1407-1413.
  148. Vallee E., Azoulay-Dupuis E., Swanson R., et al. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J. Antimicrob. Chemother., 1991, 27 (suppl. A): 31-41.
  149. Fraschini F., Scaglione F., Demartini G. Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet., 1993, 25: 189-204.
  150. Hardy D.J. Extent and spectrum of the antimicrobial activity of clarithromycin, Pediatr. Infect. Dis. J., 1993, 12: 99-105.
  151. Peters D.H., Clissold S.P. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs, 1992, 44: 117-164.
  152. Lemmen S.W., Anding K., Engels I., et al. Bactericidal activity of clarithromycin and cefaclor against Streptococcus pneumoniae and Moraxella catarrhalis in healthy volunteers. J. Antimicrob. Chemother., 1994, 33: 763-674.
  153. Scaglione F., Demartini G., Fraschini F. Distribution of clarithromycin to intracellular and extracellular sites of infection: an overview. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 380-385.
  154. Chin N.-X., Neu N.M., Labthavikul P., et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother., 1987, 31: 463-466.
  155. Dubois J., Saint-Pierre С. An in vitro susceptibility study of clarithromycin against Haemophilus, Streptococcus, Moraxella and other strains isolated from maxillary sinus aspiration. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3031.
  156. Shortridge D., Beyer J., Flamm R.K., et al. Comparative in vitro activity of clarithromycin, azithromycin and other agents against clinical isolates of Helicobacter pylori. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.10.
  157. Yamaji Е., Nakayama I., Yoshikawa E. In vitro antibacterial activity of amoxicillin, clarithromycin, metronidazole, and tinidazole against Helicobacter pylori. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. E-21.
  158. Ives Т.Е., Regenery R.L., Manzewitsch P., et al. In vitro evaluation, of macrolide antibiotics against Bartonella (Rochalimaea) henselae B.quintana and B.clizabethae via immunofluorescent antibody testing. In; The 3rd International Conference on the Macrolides, Azalides and Siroptogramins. Lisbon, 1996: abstr. 8.10.
  159. Keren G., Rubinstein E., Keysary A., et al. Evaluation of antirickettsial activity of azithromycin and clarithroinycin in in vitro systems. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 291-296.
  160. Kohno S., Koga H., Yamaguchi K., et al. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnairs’ disease. J. Antimicrob. Chemother., 1989, 24: 397-405.

© 2000-2007 НИИАХ СГМА Rambler's Top100 TopList Rambler's Top100